EXPRS2 — ExpreS2ion Biotech Holding AB Cashflow Statement
0.000.00%
Last trade - 00:00- SEK51.84m
- -SEK29.34m
- SEK7.83m
Annual cashflow statement for ExpreS2ion Biotech Holding AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | SAS | SAS | SAS | SAS | — |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -31.2 | -48.4 | -128 | -106 | -67.7 |
| Depreciation | |||||
| Non-Cash Items | 3.2 | 11.7 | 9.6 | 2.43 | -0.207 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 9.82 | -10.7 | 17.2 | 1.05 | 34 |
| Change in Accounts Receivable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -18.2 | -45.6 | -99.6 | -101 | -33.9 |
| Capital Expenditures | -0.885 | -0.715 | -0.383 | -2.02 | -0.87 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -0.194 | -100 | 106 | 0 | 22.1 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Intangibles | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -1.08 | -101 | 105 | -2.02 | 21.3 |
| Financing Cash Flow Items | -22.6 | -6.78 | -12.2 | -10.5 | -7.35 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 123 | 74.5 | 61.5 | 47.8 | 34.9 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 101 | -69.7 | 73.9 | -53.4 | 23.9 |